Skip to main content

Procyclidine Disease Interactions

There are 10 disease interactions with procyclidine.

Major

Anticholinergics (applies to procyclidine) autonomic neuropathy

Major Potential Hazard, High plausibility.

Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males. Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.

References

  1. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
Major

Anticholinergics (applies to procyclidine) GI obstruction

Major Potential Hazard, High plausibility. Applicable conditions: Gastrointestinal Obstruction, Esophageal Obstruction

Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus. Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.

References

  1. Bantz EW, Dolen WK, Chadwick EW, Nelson HS (1987) "Chronic chlorpheniramine therapy: subsensitivity, drug metabolism, and compliance." Ann Allergy, 59, p. 341-6
  2. Simons FE, Frith EM, Simons KJ (1982) "The pharmacokinetics and antihistaminic effects of brompheniramine." J Allergy Clin Immunol, 70, p. 458-64
  3. Blamoutier J (1978) "Comparative trial of two antihistamines, mequitazine and brompheniramine." Curr Med Res Opin, 5, p. 366-70
  4. (1977) "Azatadine (optimine)--a new antihistamine." Med Lett Drugs Ther, 19, p. 77-9
  5. (2002) "Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories
  6. "Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough
  7. (2002) "Product Information. Periactin (cyproheptadine)." Merck & Co., Inc
  8. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  9. (2001) "Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories
  10. (2001) "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation
  11. (2001) "Product Information. Antivert (meclizine)." Roerig Division
  12. (2001) "Product Information. Optimine (azatadine)." Schering Corporation
  13. Mevorach D (1992) "Adverse effects of atropine sulfate autoinjection." Ann Pharmacother, 26, p. 564
  14. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
  15. (2001) "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories
  16. (2001) "Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company
View all 16 references
Major

Anticholinergics (applies to procyclidine) glaucoma

Major Potential Hazard, High plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension

Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present. Because anticholinergics cause mydriasis, they may exacerbate these conditions.

References

  1. Schuller DE, Turkewitz D (1986) "Adverse effects of antihistamines." Postgrad Med, 79, p. 75-86
  2. (2002) "Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories
  3. "Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough
  4. (2002) "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham
  5. (2002) "Product Information. Periactin (cyproheptadine)." Merck & Co., Inc
  6. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  7. (2001) "Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories
  8. (2001) "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation
  9. (2001) "Product Information. Optimine (azatadine)." Schering Corporation
  10. O'Connor PS, Mumma JV (1985) "Atropine toxicity." Am J Ophthalmol, 99, p. 613-4
  11. Clearkin LG (1992) "Angle closure glaucoma precipitated by atropine." Arch Intern Med, 152, p. 880
  12. Berdy GJ, Berdy SS, Odin LS, Hirst LW (1991) "Angle closure glaucoma precipitated by aerosolized atropine." Arch Intern Med, 151, p. 1658-60
  13. Pecora JL (1979) "Malignant glaucoma worsened by miotics in a postoperative angle- closure glaucoma patient." Ann Ophthalmol, 11, p. 1412-4
  14. Holland MG (1974) "Autonomic drugs in ophthalmology: some problems and promises. Section II: Anticholinergic drugs." Ann Ophthalmol, 6, p. 661-4
  15. Kanto J (1983) "New aspects in the use of atropine." Int J Clin Pharmacol Ther Toxicol, 21, p. 92-4
  16. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
  17. (2001) "Product Information. Compazine (prochlorperazine)." SmithKline Beecham
  18. Goldstein JH (1971) "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin, 11, p. 13-34
  19. (2001) "Product Information. Cogentin (benztropine)." Merck & Co., Inc
  20. (2001) "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories
  21. (2001) "Product Information. Moban (molindone)." Gate Pharmaceuticals
  22. "Product Information. Orap (pimozide)." Gate Pharmaceuticals
  23. (2001) "Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company
View all 23 references
Major

Anticholinergics (applies to procyclidine) obstructive uropathy

Major Potential Hazard, High plausibility. Applicable conditions: Urinary Retention

In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy. Dysuria may occur and may require catheterization. Also, anticholinergic drugs may aggravate partial obstructive uropathy. Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.

References

  1. Bantz EW, Dolen WK, Chadwick EW, Nelson HS (1987) "Chronic chlorpheniramine therapy: subsensitivity, drug metabolism, and compliance." Ann Allergy, 59, p. 341-6
  2. Schuller DE, Turkewitz D (1986) "Adverse effects of antihistamines." Postgrad Med, 79, p. 75-86
  3. (2002) "Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories
  4. "Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough
  5. (2002) "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham
  6. (2002) "Product Information. Periactin (cyproheptadine)." Merck & Co., Inc
  7. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  8. (2001) "Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories
  9. (2001) "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation
  10. (2001) "Product Information. Antivert (meclizine)." Roerig Division
  11. (2001) "Product Information. Optimine (azatadine)." Schering Corporation
  12. Shutt LE, Bowes JB (1979) "Atropine and hyoscine." Anaesthesia, 34, p. 476-90
  13. O'Kelly SW, Spargo PM (1991) "Postoperative urinary retention in men." BMJ, 302, p. 1403-4
  14. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
  15. (2001) "Product Information. Compazine (prochlorperazine)." SmithKline Beecham
  16. (2001) "Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals
  17. (2001) "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories
  18. (2001) "Product Information. Moban (molindone)." Gate Pharmaceuticals
  19. "Product Information. Orap (pimozide)." Gate Pharmaceuticals
  20. (2001) "Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company
View all 20 references
Major

Anticholinergics (applies to procyclidine) tardive dyskinesia

Major Potential Hazard, High plausibility.

Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms. Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly. If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.

References

  1. Brait KA, Zagerman AJ (1977) "Dyskinesias after antihistamine use ." N Engl J Med, 296, p. 111
  2. Jones B, Lal S (1985) "Tardive dyskinesia uncovered after ingestion of Sominex, an over-the- counter drug." Can J Psychiatry, 30, p. 370-1
  3. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  4. Yassa R (1985) "Antiparkinsonian medication withdrawal in the treatment of tardive dyskinesia: a report of three cases." Can J Psychiatry, 30, p. 440-2
  5. Burnett GB, Prange AJ Jr, Wilson IC, Jolliff LA, Creese IC, Synder SH (1980) "Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism." Neuropsychobiology, 6, p. 109-20
  6. Kiloh LG, Smith JS, Williams SE (1973) "Antiparkinson drugs as causal agents in tardive dykinesia." Med J Aust, 2, p. 591-3
  7. (2001) "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories
View all 7 references
Major

Antiperistaltic agents (applies to procyclidine) infectious diarrhea

Major Potential Hazard, High plausibility. Applicable conditions: Infectious Diarrhea/Enterocolitis/Gastroenteritis

The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria. These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics. Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged. In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool. Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.

References

  1. Brown JW (1979) "Toxic megacolon associated with loperamide therapy." JAMA, 241, p. 501-2
  2. Walley T, Milson D (1990) "Loperamide related toxic megacolon in Clostridium difficile colitis." Postgrad Med J, 66, p. 582
  3. (2001) "Product Information. Imodium (loperamide)." Janssen Pharmaceuticals
  4. Marshall WF Jr, Rosenthal P, Merritt RJ (1989) "Atropine therapy and paralytic ileus in an infant." J Pediatr Gastroenterol Nutr, 9, p. 532-4
  5. (1975) "Lomotil for diarrhea in children." Med Lett Drugs Ther, 17, p. 104
  6. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
View all 6 references
Moderate

Anticholinergics (applies to procyclidine) cardiac disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease

Anticholinergics block vagal inhibition of the SA nodal pacemaker. Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease. Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.

References

  1. Schuller DE, Turkewitz D (1986) "Adverse effects of antihistamines." Postgrad Med, 79, p. 75-86
  2. Lowenthal DT, Reidenberg MM (1972) "The heart rate response to atropine in uremic patients, obese subjects before and during fasting, and patients with other chronic illnesses." Proc Soc Exp Biol Med, 139, p. 390-3
  3. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  4. (2001) "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation
  5. (2001) "Product Information. Antivert (meclizine)." Roerig Division
  6. Lunde P (1976) "Ventricular fibrillation after intravenous atropine for treatment of sinus bradycardia." Acta Med Scand, 199, p. 369-71
  7. Cooper MJ, Abinader EG (1979) "Atropine-induced ventricular fibrillation: case report and review of the literature." Am Heart J, 97, p. 225-8
  8. Das G, Talmers FN, Weissler AM (1975) "New observations on the effects of atropine on the sinoatrial and atrioventricular nodes in man." Am J Cardiol, 36, p. 281-5
  9. Knoebel SB, McHenry PL, Phillips JF, Widlansky S (1974) "Atropine-induced cardioacceleration and myocardial blood flow in subjects with and without coronary artery disease." Am J Cardiol, 33, p. 327-32
  10. Bradshaw EG (1976) "Dysrhythmias associated with oral surgery." Anaesthesia, 31, p. 13-7
  11. Horgan J (1973) "Atropine and ventricular tachyarrhythmia." JAMA, 223, p. 693
  12. Zsigmond EK, Matsuki A, Sharafabadi C (1973) "Atropine and cardiac arrhythmia." N Engl J Med, 288, p. 635
  13. Massumi RA, Mason DT, Amsterdam EA, DeMaria A, Miller RR, Scheinman MM, Zelis R (1972) "Ventricular fibrillation and tachycardia after intravenous atropine for treatment of bradycardias." N Engl J Med, 287, p. 336-8
  14. Valentin N, Staffeldt H, Kyst A (1984) "Effect of i.v. atropine on cardiac rhythm, heart rate, blood pressure and airway secretion during isoflurane anaesthesia." Acta Anaesthesiol Scand, 28, p. 621-4
  15. Lazzari JO, Benchuga EG, Elizari MV, Rosenbaum MB (1982) "Ventricular fibrillation after intravenous atropine in a patient with atrioventricular block." Pacing Clin Electrophysiol, 5, p. 196-200
  16. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
View all 16 references
Moderate

Anticholinergics (applies to procyclidine) liver disease

Moderate Potential Hazard, Moderate plausibility.

The clearance of anticholinergics may be decreased in the presence of liver disease. Therapy with anticholinergics should be administered cautiously and may require less frequent dosing to avoid adverse effects in patients with liver disease.

References

  1. Glazko AJ, Dill WA, Young RM, Smith TC, Ogilvie RI (1974) "Metabolic disposition of diphenhydramine." Clin Pharmacol Ther, 16, p. 1066-76
  2. Meredith CG, Christian CD Jr, Johnson RF, Madhavan SV, Schenker S (1984) "Diphenhydramine disposition in chronic liver disease." Clin Pharmacol Ther, 35, p. 474-9
  3. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
Minor

Anticholinergics (applies to procyclidine) hypertension

Minor Potential Hazard, Moderate plausibility.

Cardiovascular effects of anticholinergics may exacerbate hypertension. Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.

References

  1. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  2. (2001) "Product Information. Antivert (meclizine)." Roerig Division
  3. (2001) "Product Information. Marezine (cyclizine)." Glaxo Wellcome
  4. Valentin N, Staffeldt H, Kyst A (1984) "Effect of i.v. atropine on cardiac rhythm, heart rate, blood pressure and airway secretion during isoflurane anaesthesia." Acta Anaesthesiol Scand, 28, p. 621-4
  5. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
  6. (2001) "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories
  7. (2002) "Product Information. Atropisol (atropine ophthalmic)." Ciba Vision Ophthalmics
View all 7 references
Minor

Anticholinergics (applies to procyclidine) hyperthyroidism

Minor Potential Hazard, Low plausibility.

In general, agents with anticholinergic activity may exacerbate hyperthyroidism. Therapy with anticholinergics should be administered cautiously in patients with hyperthyroidism. Thyroid levels should be monitored if usage is prolonged.

References

  1. (2002) "Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories
  2. "Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough
  3. (2002) "Product Information. Periactin (cyproheptadine)." Merck & Co., Inc
  4. (2001) "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation
  5. (2001) "Product Information. Antivert (meclizine)." Roerig Division
  6. (2001) "Product Information. Optimine (azatadine)." Schering Corporation
  7. (2022) "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics
  8. (2001) "Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company
View all 8 references

Procyclidine drug interactions

There are 330 drug interactions with procyclidine.

Procyclidine alcohol/food interactions

There are 2 alcohol/food interactions with procyclidine.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.